BiotechTube

Erenumab Prefilled Syringe

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Facial Pain

Conditions

Facial Pain, Rhinosinusitis

Trial Timeline

Feb 10, 2021 → Jul 11, 2023

NCT ID
NCT04249427

About Erenumab Prefilled Syringe

Erenumab Prefilled Syringe is a approved stage product being developed by Amgen for Facial Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT04249427. Target conditions include Facial Pain, Rhinosinusitis.

What happened to similar drugs?

3 of 7 similar drugs in Facial Pain were approved

Approved (3) Terminated (0) Active (4)
✅BOTOXAbbVieApproved
✅OnabotulinumtoxinA + KYBELLAAbbVieApproved
✅BOTOX®/VISTABEL®AbbVieApproved
🔄EMLA CreamSanofiPhase 3
🔄Botulinum toxin type AIpsenPhase 3
🔄FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
🔄FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04249427ApprovedCompleted

Competing Products

13 competing products in Facial Pain

See all competitors
ProductCompanyStageHype Score
BOTOXAbbVieApproved
43
OnabotulinumtoxinA + KYBELLAAbbVieApproved
47
BOTOX®/VISTABEL®AbbVieApproved
43
RapamunePfizerPhase 1
29
EMLA CreamSanofiPhase 3
40
Diflucortolone valerate (BAY866146)BayerPre-clinical
23
Botulinum toxin type AIpsenPhase 3
37
IPN10200 + IPN10200 Placebo + DysportIpsenPhase 1/2
36
IPN59011 + Azzalure + PlaceboIpsenPhase 1
18
Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)BaxterPhase 2
32
Metyrosine + PlaceboBausch HealthPhase 2
21
FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
30
FMX103 minocycline foam 1.5% + Vehicle foamVyne TherapeuticsPhase 3
30